[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3065
81. Galderisi F, Stork L, Li J, Mori M, Mongoue-Tchokote S, Huang J: Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Oct;53(4):543-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.
  • BACKGROUND: Residual disease or rapidity of response to induction therapy is among the most powerful predictors of outcome in pediatric acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Drug Screening Assays, Antitumor / methods. Flow Cytometry / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Child. Child, Preschool. Drug Resistance, Neoplasm. Female. Humans. Infant. Karyotyping. Male. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2009 Jan;33(1):46-53 [18639340.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4036-45 [10590047.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Cytometry. 2000 Jun 1;40(2):167-71 [10805937.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1094-9 [10910927.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1619-20 [10979670.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1066-71 [11455975.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4109-15 [12010814.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):1190-1 [12199807.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):376-85 [12877664.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1041-9 [6336986.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Cancer Lett. 1988 Aug 30;41(3):323-32 [3165705.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 15;40(2):171-85 [2766242.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1807-15 [2685179.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1449-63 [2207320.001]
  • [Cites] Leukemia. 1992 Nov;6(11):1121-8 [1434793.001]
  • [Cites] Drugs. 1992 Nov;44(5):690-708 [1280562.001]
  • [Cites] Crit Rev Oncol Hematol. 1993 Oct;15(2):99-111 [8117418.001]
  • [Cites] Lancet. 1995 Jan 21;345(8943):143-8 [7823668.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1292-5 [7632935.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):389-98 [8636748.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2959-65 [9108416.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26 [9134309.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):603-6 [9207407.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):190-5 [9628428.001]
  • [Cites] Blood. 1998 Jul 1;92(1):259-66 [9639525.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1838 [9716617.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):6-12 [10029805.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):233-8 [10472556.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4223-5 [15718422.001]
  • [Cites] Leuk Lymphoma. 2005 Jun;46(6):833-40 [16019527.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Cytometry B Clin Cytom. 2007 May;72(3):189-95 [17226861.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [CommentIn] Pediatr Blood Cancer. 2009 Oct;53(4):525-6 [19642213.001]
  • (PMID = 19499583.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024140; United States / NCRR NIH HHS / RR / UL1 RR024140; United States / NCRR NIH HHS / RR / UL1 RR024140-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS123064; NLM/ PMC2775428
  •  go-up   go-down


82. Wapenaar W, Barkema HW, O'Handley RM, Bartels CJ: Use of an enzyme-linked immunosorbent assay in bulk milk to estimate the prevalence of Neospora caninum on dairy farms in Prince Edward Island, Canada. Can Vet J; 2007 May;48(5):493-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 11 farms that were considered positive based on bulk milk samples, blood samples were collected from all adult cows in September 2005, in conjunction with a 4th bulk milk sample on the same day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Diagn Invest. 1995 Apr;7(2):177-82 [7619898.001]
  • [Cites] J Dairy Sci. 1992 Feb;75(2):423-34 [1560137.001]
  • [Cites] J Am Vet Med Assoc. 1996 May 1;208(9):1441-4 [8635995.001]
  • [Cites] Vet Parasitol. 1996 Sep 2;64(3):197-205 [8888553.001]
  • [Cites] Vet Parasitol. 1996 Dec 2;67(1-2):1-59 [9011014.001]
  • [Cites] Vet Parasitol. 1997 Feb;68(3):251-60 [9066070.001]
  • [Cites] Clin Diagn Lab Immunol. 1997 May;4(3):270-4 [9144362.001]
  • [Cites] Arch Virol Suppl. 1991;3:245-51 [9210948.001]
  • [Cites] Vet Rec. 1998 Apr 11;142(15):385-91 [9586130.001]
  • [Cites] Vet Microbiol. 1999 Jan;64(2-3):197-222 [10028173.001]
  • [Cites] Vet Rec. 1999 May 8;144(19):519-22 [10378278.001]
  • [Cites] Vet Rec. 1999 May 8;144(19):527-9 [10378280.001]
  • [Cites] Vet Parasitol. 2005 Mar 31;128(3-4):209-18 [15740858.001]
  • [Cites] Vet Parasitol. 2005 Apr 20;129(1-2):67-75 [15817205.001]
  • [Cites] Prev Vet Med. 2005 May 10;68(2-4):165-79 [15820114.001]
  • [Cites] Vet Parasitol. 2005 Aug 10;131(3-4):235-46 [15970385.001]
  • [Cites] Trends Parasitol. 2005 Dec;21(12):558-61 [16223599.001]
  • [Cites] Vet Parasitol. 2006 Mar 31;136(3-4):243-50 [16406330.001]
  • [Cites] Vet Parasitol. 2006 Apr 15;137(1-2):17-27 [16417972.001]
  • [Cites] Prev Vet Med. 2006 May 17;74(2-3):120-9 [16417934.001]
  • [Cites] Vet Parasitol. 2007 Jan 31;143(2):166-73 [16989951.001]
  • [Cites] Int J Parasitol. 1999 Aug;29(8):1195-200 [10576571.001]
  • [Cites] Prev Vet Med. 2000 Mar 29;44(1-2):1-7 [10727740.001]
  • [Cites] Theriogenology. 1998 May;49(7):1311-6 [10732068.001]
  • [Cites] Theriogenology. 1999 Jul 15;52(2):233-45 [10734391.001]
  • [Cites] Prev Vet Med. 1999 Oct 19;47(1-2):91-105 [11018737.001]
  • [Cites] Can Vet J. 2000 Nov;41(11):864-6 [11126492.001]
  • [Cites] Int J Parasitol. 2001 Feb;31(2):209-15 [11239942.001]
  • [Cites] J Clin Microbiol. 2001 Nov;39(11):3851-7 [11682497.001]
  • [Cites] Clin Diagn Lab Immunol. 2001 Nov;8(6):1049-55 [11687438.001]
  • [Cites] Vet Rec. 2002 Feb 9;150(6):182-3 [11888111.001]
  • [Cites] Can Vet J. 2002 Jun;43(6):454-9 [12058571.001]
  • [Cites] Vet Parasitol. 2002 Dec 11;110(1-2):35-44 [12446088.001]
  • [Cites] Int J Parasitol. 2003 Dec;33(14):1631-40 [14636679.001]
  • [Cites] Vet Parasitol. 2004 Feb 26;120(1-2):55-63 [15019143.001]
  • [Cites] Biometrics. 1989 Mar;45(1):255-68 [2720055.001]
  • [Cites] Dtsch Tierarztl Wochenschr. 1989 Nov-Dec;96(10):475-86 [2557195.001]
  • [Cites] Vet Q. 1991 Apr;13(2):118-20 [1882491.001]
  • [Cites] Vet Microbiol. 1995 Jul;45(2-3):185-9 [7571369.001]
  • (PMID = 17542367.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Protozoan
  • [Other-IDs] NLM/ PMC1852591
  •  go-up   go-down


83. Bampton PA, Schloithe A, Bull J, Fraser RJ, Padbury RT, Watson DI: Improving surveillance for Barrett's oesophagus. BMJ; 2006 Jun 3;332(7553):1320-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All adult patients diagnosed with Barrett's oesophagus were included.
  • [MeSH-minor] Adult. Guideline Adherence. Humans. Mass Screening / methods. Medical Audit. Practice Guidelines as Topic. Retrospective Studies. South Australia


8
Advertisement
4. Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P, Gronemeyer H: HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol; 2007;39(7-8):1500-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
  • We have compared the growth inhibitory and apoptogenic potential of the pan-HDACi SAHA and the sub-class I selective HDAC inhibitor MS275, as well as valproic acid (VPA) on glucocorticoid sensitive and resistant B (B-ALL) and T (T-ALL) cell acute lymphoblastic leukemia cells and patients blasts.
  • In contrast, to our previous results with U937 acute myeloid leukemia (AML) cells which showed a similar activity of MS275 and SAHA in growth inhibition and apoptosis induction, both B and T-ALL cells were much more efficiently killed by SAHA and VPA than by MS275.
  • [MeSH-major] Apoptosis. Benzamides / pharmacology. Burkitt Lymphoma / pathology. Drug Resistance, Neoplasm. Glucocorticoids / pharmacology. Histone Deacetylase Inhibitors. Hydroxamic Acids / pharmacology. Leukemia-Lymphoma, Adult T-Cell / pathology. Pyridines / pharmacology

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499001.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Glucocorticoids; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Pyridines; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 1ZNY4FKK9H / entinostat; 58IFB293JI / vorinostat; 614OI1Z5WI / Valproic Acid; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


85. Dai L, Gast A, Horska A, Schrappe M, Bartram CR, Hemminki K, Kumar R, Bermejo JL: A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer; 2009 Jul;52(7):819-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes.
  • BACKGROUND: Inherited genetic variants in critical genes can putatively modulate susceptibility to childhood acute lymphoblastic leukemia (ALL).
  • METHODS: We used allelic discrimination method to genotype 19 polymorphisms in the transforming growth factor-beta1 (TGF-beta1), transforming growth factor-beta receptor 1 (TGF-betaR1) and transforming growth factor-beta receptor 2 (TGF-betaR2) genes in 460 cases of childhood acute ALL and 552 ethnically matched controls.
  • [MeSH-major] Polymorphism, Single Nucleotide / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / genetics
  • [MeSH-minor] Adult. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Case-Control Studies. Child. Female. Haplotypes / genetics. Humans. Male. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19229971.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down






Advertisement